Publications by authors named "Carlos DeCastro"

Claim this Profile
P
Patient-Reported Meaningful Change in Symptoms and Impacts of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Three Phase III Clinical Trials of Iptacopan.
Carlos DeCastro, Phillip Sheinberg, Bing Han, Susan Vallow, Georgina Bermann

Patient· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
Kathryn E Hudson, David Rizzieri, Samantha M Thomas, Thomas W LeBlanc, Zachary Powell, Carlos DeCastro

Br J Haematol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone ("VCD-Lite") in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma.
Sascha A Tuchman, Joseph O Moore, Carlos D DeCastro, Zhiguo Li, Emily Sellars

J Geriatr Oncol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma.
Danielle Brander, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro

Leuk Lymphoma· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-induction therapy decisions based on day 14 bone marrow biopsy in acute myeloid leukemia.
Tod A Morris, Carlos M DeCastro, Louis F Diehl, Jon P Gockerman, Anand S Lagoo

Leuk Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
Mark C Lanasa, Patricia H Davis, Michael Datto, Zhiguo Li, Jon P Gockerman, Carlos M DeCastro

Leuk Lymphoma· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
Christopher A Crout, Liang-Piu Koh, Jon P Gockerman, Joseph O Moore, Carlos Decastro

Cancer Invest· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
Daphne R Friedman, J Brice Weinberg, William T Barry, Barbara K Goodman, Alicia D Volkheimer, Carlos M Decastro

Clin Cancer Res· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
David A Rizzieri, Jenny A O'Brien, Gloria Broadwater, Carlos M Decastro, Prakash Dev

Cancer· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelodysplastic syndromes.
Peter L Greenberg, Eyal Attar, Minoo Battiwalla, John M Bennett, Clara D Bloomfield, Carlos M DeCastro

J Natl Compr Canc Netw· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Arati V Rao, Islam R Younis, Gregory J Sand, Ivan Spasojevic, David J Adams, Carlos M Decastro

Leuk Lymphoma· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
J Brice Weinberg, Alicia D Volkheimer, Youwei Chen, Bethany E Beasley, Ning Jiang, Carlos M Decastro

Am J Hematol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
David A Rizzieri, Liang Piu Koh, Gwynn D Long, Cristina Gasparetto, Keith M Sullivan, Carlos Decastro

J Clin Oncol· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-intense cyclophosphamide and etoposide for patients with refractory or high-risk non-Hodgkin's lymphoma.
Jeffrey Talbot, Valerie K Ibom, David A Rizzieri, Robert Barrier, Donna Niedzwieki, Carlos M DeCastro

Clin Lymphoma· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma.
David A Rizzieri, Gamal Akabani, Michael R Zalutsky, R Edward Coleman, Scott D Metzler, Carlos DeCastro

Blood· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
David A Rizzieri, Gregory J Sand, Dean McGaughey, Joseph O Moore, Carlos DeCastro

Cancer· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan.
Jun-Ichi Nishimura, Yuzuru Kanakura, Russell E Ware, Tsutomu Shichishima, Hideki Nakakuma, Carlos M Decastro

Medicine (Baltimore)· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
Valerie K Ibom, Robert G Prosnitz, Jerald Z Gong, Joseph O Moore, Carlos M DeCastro

Clin Lymphoma· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose cyclophosphamide and etoposide for patients with refractory acute myeloid leukemia: a case series.
Jeffrey Talbot, David A Rizzieri, Carlos M DeCastro, Joseph O Moore, Patrick Buckley

Am J Hematol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased expression of anti-apoptosis genes in peripheral blood cells from patients with paroxysmal nocturnal hemoglobinuria.
Matthew M Heeney, Susan M Ormsbee, M Anthony Moody, Thad A Howard, Carlos M DeCastro

Mol Genet Metab· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
David A Rizzieri, Valerie K Ibom, Joseph O Moore, Carlos M DeCastro, Gary L Rosner

Clin Cancer Res· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Adam J Bass, Jon P Gockerman, Eve Hammett, Carlos M DeCastro, David J Adams

J Clin Oncol· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Lewis R Silverman, Erin P Demakos, Bercedis L Peterson, Alice B Kornblith, Jimmie C Holland, Carlos M DeCastro

J Clin Oncol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.
Alice B Kornblith, James E Herndon, Lewis R Silverman, Erin P Demakos, Rosalie Odchimar-Reissig, Carlos DeCastro

J Clin Oncol· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Steven L McCune, Jon P Gockerman, Joseph O Moore, Carlos M Decastro, Adam J Bass

Leuk Lymphoma· May 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis